COMPANY PROFILE

Marius Pharmaceuticals

Explore full profile

Focusing on therapies designed for hypogonadism or Testosterone Deficiency

Raleigh, United StatesFounded 2017Biotech & Life Sciences

Valuation $25–50M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Marius Pharmaceuticals

Marius Pharmaceuticals is a healthcare company specializing in the development and commercialization of innovative testosterone therapies aimed at addressing men's health issues. Operating primarily in the pharmaceutical and healthcare markets, Marius Pharmaceuticals targets adult men experiencing conditions related to low testosterone levels, such as hypogonadism. The company's flagship product, KYZATREX, is designed to improve testosterone levels and alleviate associated symptoms like fatigue, decreased libido, and mood swings. Marius Pharmaceuticals generates revenue through the sale of KYZATREX and other related healthcare products, leveraging a business model that combines direct sales to healthcare providers and partnerships with pharmacies. The company is committed to advancing preventative healthcare and improving the quality of life for men globally.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Raleigh, United States
Employees: 26
Open positions: 4
Dealroom signal: 88.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Mentech, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCEquity / VC	Oct 2021	$6M	$24M	Undisclosed	—
EARLY VC✓Equity / VC	Jun 2020	$2M	$105M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Marius Pharmaceuticals website traffic

Latest recorded traffic for Marius Pharmaceuticals is 4.4K monthly website visits, up 29.4% over the last three months. Marius Pharmaceuticals's team grew 36.8% over the past year.

Latest monthly visits4.4K 3-month web change+29.4% 1-year team growth+36.8%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Territory Sales Representative - Southern CaliforniaRaleigh, NC, United States · Sales · Aug 4, 2026 Territory Sales Representative - New YorkNew York, United States · Sales · Aug 1, 2026 Territory Sales Representative - Dallas/HoustonRaleigh, NC, United States · Sales · Aug 1, 2026 Territory Sales Representative - South FloridaRaleigh, NC, United States · Sales · Jul 30, 2026

4 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNeusignal TherapeuticsTherapeutic drugs for Central Nervous System diseases	Tokyo, Japan	Operational	11	$73M	$164M
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
NENeurOpResearch company developing different drug compounds	Atlanta, United States	Operational
KPKringle PharmaKringle Pharma is a late clinical-stage biopharmaceutical company focused on research and development of regenerative medicines	Toyonaka, Japan	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
ABAnnexon BiosciencesBiotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders	San Francisco, United States	Operational